Drug profile · INN
mupirocin
APO-MUPIROCIN
mupirocin (APO-MUPIROCIN) is a isoleucyl-trna synthetase inhibitor. Associated with GlaxoSmithKline. Route of administration: topical. Current US regulatory status: approved.
Drug details — mupirocin
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 1
- Programs
- 2
- Data quality
- 0.89
Quick answer
mupirocin (APO-MUPIROCIN) is a isoleucyl-trna synthetase inhibitor. Associated with GlaxoSmithKline. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Isoleucyl-tRNA synthetase inhibitor
Primary target: Isoleucine--tRNA ligase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is mupirocin?
mupirocin (APO-MUPIROCIN) is a isoleucyl-trna synthetase inhibitor. Associated with GlaxoSmithKline. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for mupirocin?
APO-MUPIROCIN is a marketed brand name for mupirocin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mupirocin?
mupirocin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.